Clinical Trial Update: Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating the combination of ofatumumab and bortezomib in patients with low-grade B-cell non-Hodgkin lymphoma that relapsed after ritux…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: Brown University | Conditions: Lymphoma, Non-Hodgkins | Phase 2 | Status: TERMINATED | Results posted: 2015-08-11